Therapeutic effects of resveratrol on OVA-induced allergic rhinitis in mice and immune mechanisms
10.3969/j.issn.1001-1978.2021.02.013
- Author:
Dong-Cai LI
1
;
Peng WANG
1
;
Sheng LI
1
;
Qiao-Lian YU
1
;
Jian-Pian LAN
1
;
Bao-Hui CHENG
1
Author Information
1. Longgang E. N. T Hospital, Shenzhen Key Lab of E. N. T, Institute of E. N. T, Dept of Otolaryngology
- Publication Type:Journal Article
- Keywords:
allergic rhinitis;
interleukin-13;
interleukin-4;
resveratrol;
specific immunoglobulin;
T helper 2 cell
- From:
Chinese Pharmacological Bulletin
2021;37(2):215-220
- CountryChina
- Language:Chinese
-
Abstract:
Aim To investigate the curative effects of resveratrol on OVA induced allergic rhinitis in mice and the underlying immune mechanisms. Methods Balb/c mice (female, 6 weeks) were divided randomly into normal control ( NC) group, allergic rhinitis (AR) group, high dose resveratrol treatment group (RH), low dose resveratrol treatment group (RL), and dexamethasone treatment group ( Dex). RL, RH and Dex group were oral administered with resveratrol 30 mg • kg"1, resveratrol 100 mg • kg"1 and dexamethasone 10 mg • kg"1, respectively. After the treat-ment , the sneezing and nasal rubbing behaviors of mice in all the group were recorded and HE was performed to assess the inflammatory cell infiltration in nasal tissues. The sera levels of allergic cytokines were determined with ELISA assay. The percentage of CD4+ GA- TA3 + T cells in spleen of each group was further recorded by flow cytometry. Results Compared with AR group, treatment with resveratrol (100 mg - kg"1) reduced the sneezing and nasal rubbing behaviors signifi-cantly and improved inflammatory cell infiltration in nasal tissues. The up-regulated sera levels of IL-4, IL- 13 and OVA-sIgE in AR group were reversed by RH, and ratios CD4+ GATA3 + Th2 cells in spleen of RH were also down-regulated parallelly. Conclusions RH treatment could improve the allergic related symptoms of OVA-induced allergic rhinitis, which is associated with down-regulated sera levels of IL-4, IL-13 and OVA-sIgE and ratios of CD4+ GATA3 + Th2 cells in spleen of mouse model.
